BOUCHERVILLE, Quebec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC (TSXV: LSL) ("the Company" or "LSL Pharma "), a Canadian integrated pharmaceutical company, is pleased to announce the appointment of Mr. Luc Mainville as Senior Vice President and Chief Financial Officer effective December 4, 2023.

Mr. Mainville brings extensive experience in the capital markets and life sciences industry. He is recognized for his financial and operational leadership having been associated with several fast-growing companies. In an executive management career spanning more than 30 years, he has been involved in numerous public and private financings totalling in excess of $500 million and more than 50 corporate transactions, including initial public offerings, licensing, as well as mergers and acquisitions.

Over the last five years, Mr. Mainville acted as Senior Vice President and Chief Financial Officer of Valeo Pharma, a fast-growing Canadian pharmaceutical company. During his tenure at Valeo, he raised in excess of $100 million helping Valeo increase its revenues 15 fold. Prior to that, he held senior management positions with various life sciences companies, including Acerus Pharma, Cardiome Pharma, Neopharm Labs and LAB Research. Prior to his career in the life sciences sector, he was partner with KPMG, LLP. He holds an MBA from McGill University.

Luc Mainville has been Director of LSL Pharma since February 2023, and will relinquish his board position when joining the Company.

"The appointment of Luc Mainville represents an important step in creating a best-in-class highly performant management team at LSL Pharma," said François Roberge, President and CEO of LSL Pharma. "Luc is a seasoned professional with an excellent knowledge of the life sciences industry, capital markets and public financings. We are delighted that he is joining us and we are looking forward to benefitting from his extensive experience. He will be a key contributor in carrying out our strategy, which includes growing organically and through acquisitions."

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Company's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents.

Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Company may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

ABOUT LSL PHARMA GROUP INC.

LSL Pharma is an integrated Canadian pharmaceutical company specializing in the development, manufacturing and distribution of high-quality natural health products and dietary supplements in solid dosage forms, as well as high-quality sterile ophthalmic pharmaceuticals. For further information, please visit the following websites , and .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT :
François Roberge, President and CEO
Telephone: 514 664-7700
E-mail: Investors@groupelslpharma.com